Page last updated: 2024-11-06

2,5-dimethoxyamphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,5-dimethoxyamphetamine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62787
CHEMBL ID8642
SCHEMBL ID1740902
MeSH IDM0110357

Synonyms (46)

Synonym
NCI60_003383
1-(2,5-dimethoxyphenyl)-2-aminopropane
benzeneethanamine, 2,5-dimethoxy-alpha-methyl-
einecs 220-540-2
2,5-dimethoxy-alpha-methylphenethylamine
u-10,648
1-(2,5-dimethoxyphenyl)isopropylamine
dea no. 7396
2,5-dimethoxy-alpha-methylbenzeneethanamine
2-(2-aminopropyl)hydroquinone dimethyl ether
dimethoxyamphetamine, 2,5-
benzeneethanamine,2,5-dimethoxy-.alpha.-methyl-(.+/-.)-
DB01465
2,5-dimethoxyamphetamine
NCGC00168269-01
L000883
CHEMBL8642 ,
bdbm50005251
1-(2,5-dimethoxyphenyl)propan-2-amine
(+/-)2-(2,5-dimethoxy-phenyl)-1-methyl-ethylamine
2-(2,5-dimethoxy-phenyl)-1-methyl-ethylamine(2,5-dma)
C-1739 ,
unii-oim1536tqq
2801-68-5
phenethylamine, 2,5-dimethoxy-alpha-methyl-
oim1536tqq ,
(+/-)-2,5-dimethoxyamphetamine
2,5-dimethoxyamphetamine, (+/-)-
2,5-dma
2,5-dimethoxy-amphetamine
benzeneethanamine, 2,5-dimethoxy-.alpha.-methyl-, (+/-)-
j46.485f ,
SCHEMBL1740902
benzeneethanamine, 2,5-dimethoxy-.alpha.-methyl-
benzeneethanamine, 2,5-dimethoxy-.alpha.,-methyl
phenethylamine, 2,5-dimethoxy-.alpha.-methyl-
2,5-dimethoxy-.alpha.-methylphenethylamine
1-(2,5-dimethoxyphenyl)-2-propanamine
LATVFYDIBMDBSY-UHFFFAOYSA-N
amphetamine, 2,5-dimethoxy
(+/-) -1-(2,5-dimethoxyphenyl)-2-aminopropane
DTXSID2091540
2,5-dimethoxy-alpha-methyl-benzeneethanamine
Q27092772
1-(2 5-dimethoxyphenyl)-2-aminopropane&
PD008848
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki5.40420.00020.667710.0000AID4762; AID5263; AID5270; AID5725
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki4.11190.00010.601710.0000AID1442357; AID1442358; AID1442359; AID1442363; AID385347; AID5263; AID5270; AID5531; AID5535
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki1.02000.00010.739610.0000AID3695
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki2.70550.00000.385510.0000AID1442359; AID389734
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki1.02000.00031.29679.2440AID3695
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki1.02000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki1.02000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki5.20000.00020.590910.0000AID5263; AID5270
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki4.72000.00000.338510.0000AID1442363
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd0.14790.00042.58328.5114AID6405; AID6406
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd0.14790.00012.62198.5114AID6405; AID6406
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd0.14790.00012.29338.5114AID6405; AID6406
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd0.14790.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd0.14790.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd0.14790.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd0.14790.00042.47358.5114AID6405; AID6406
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd0.14790.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd0.14790.00012.70068.5114AID6405; AID6406
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd0.14790.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd0.14790.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd0.14790.00082.62148.5114AID6405; AID6406
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd0.14790.02342.74218.5114AID6405; AID6406
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd0.14790.00082.62148.5114AID6405; AID6406
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID88883Hallucinogenic activity i.e; ratio of effective dose of mescaline to the effective dose in human1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID227926Equilibrium constant for DNB complex formation1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID192078Percent of animals selecting drug liver was determined at a dose of 8.14 intraperitoneally. (No. of animals disrupted:1)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
AID385349Lipophilicity of compound by immobilized artificial membrane column containing phosphatidylcholine head groups HPLC2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID241440Inhibitory concentration against monoamine oxidase A in rat brain mitochondrial suspension2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling.
AID178403Effective dose in rats trained on 1 mg/kg DOM.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID385347Displacement of [3H]ketanserin from 5HT2A receptor in Sprague-Dawley rat brain by liquid scintillation spectroscopy2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID6405Binding affinity at rat 5-hydroxytryptamine receptor.1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID5797Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID192077Percent of animals selecting drug liver was determined at a dose of 40.70 intraperitoneally. (No. of animals disrupted:4)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
AID5270Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID91217Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
AID176930Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 3.0 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID5226Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors.
AID5725Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists.
AID1442359Displacement of [125I]DOI from recombinant human 5HT2A expressed in Syrian hamster AV12 cell membranes2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID1442363Displacement of [3H]ketanserin from rat 5HT2A expressed in mouse NIH/3T3 cell membranes after 30 mins by scintillation counting method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID5257Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
AID3695Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID167866Hyperthermic potency in rabbit relative to DOM1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID5263Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID23503Partition coefficient (logP)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID19561Hill coefficient as determined.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
AID2330285-HT1C selectivity was defined as the ratio between Ki(5-HT2)/Ki(5-HT1C)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID176208Effective dose was determined for the behavioral (interoceptive cues) activity of rats1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Studies on several 7-substituted N,N-dimethyltryptamines.
AID1146450Competitive antagonist activity at 5-HT serotonin receptor in Sprague-Dawley rat stomach fundus model assessed as inhibition of 5-HT-induced contractile response1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues.
AID3696Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID19263Log value of hallucinogenic activity was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID192075Percent of animals selecting drug liver was determined at a dose of 32.56 intraperitoneally. (No. of animals disrupted:1)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
AID5299Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID5531Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Ring substituted analogues of 5-aminomethyl-10,11-dihydro-dibenzo[a,d]cycloheptene (AMDH): potential modes of binding to the 5-HT(2A) receptor.
AID4762Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID93042Hallucinogenic potency was determined in humans1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID1131956Hallucinogenic activity in human1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Structure-activity studies on hallucinogenic amphetamines using molecular connectivity.
AID1442357Displacement of [3H]ketanserin from 5HT2A in Sprague-Dawley rat cortex membranes measured after 15 mins2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID192071Percent of animals selecting drug liver was determined at a dose of 16.28 intraperitoneally. (No. of animals disrupted:1)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
AID5535Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists.
AID389734Displacement of [3H]ketanserin from 5HT2A receptor expressed in NIH3T3 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
AID192076Percent of animals selecting drug liver was determined at a dose of 4.07 intraperitoneally. ( No. of animals disrupted:0)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.
AID1442358Displacement of [3H]DOB from 5HT2A in Sprague-Dawley rat cortex membranes measured after 15 mins by scintillation counting method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID90250Human hallucinogenic activity relative to mescaline1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (38.46)18.7374
1990's6 (23.08)18.2507
2000's7 (26.92)29.6817
2010's3 (11.54)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.59 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]